By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



201 President-Kennedy Avenue
Suite PK-R210
Montreal  Quebec  H2X 3Y7  Canada
Phone: 514-788-7800 Fax: 514-788-7801




Company News
ASCO15: AngioChem Presents ANG1005 Data On Breast Cancer Patients With Brain Metastasis At The 2015 American Society For Clinical Oncology Annual Meeting 6/1/2015 11:32:11 AM
AngioChem Publishes Data On ANG4043, A Brain-Penetrant Anti-HER2 Monoclonal Antibody For Treatment Of Brain Metastases 12/9/2014 9:50:07 AM
AngioChem Presents Positive Data On ANG1005 In Brain Mets, Launches Phase 2, Gets Orphan Drug/Fast Track 5/30/2014 10:09:58 AM
AngioChem's ANG1005 Received Fast Track And Orphan Drug Designation From FDA For The Treatment Of Glioblastoma Multiforme 5/30/2014 6:38:21 AM
AngioChem To Present Clinical Data At The American Society of Clinical Oncology 2014 Annual Meeting 5/15/2014 9:53:48 AM
Preclinical Data On AngioChem Pain Program Published In Journal Of Clinical Investigation 2/18/2014 9:58:18 AM
AngioChem Demonstrates Peptide Antibody Conjugate That Successfully Crosses The Blood Brain Barrier And Increases Survival In HER-2 Positive Brain Tumors 12/16/2013 9:39:04 AM
AngioChem To Present Data On Its Lead Oncology Compounds At The 2013 San Antonio Breast Cancer Symposium 12/5/2013 7:37:37 AM
AngioChem’s ANG1005 For Primary Brain Cancer And Brain Metastasis Selected As A Top 10 Project To Watch 11/12/2013 9:17:32 AM
Phase 2 Clinical Data for AngioChem's Lead Drug Candidate, ANG1005, in Breast Cancer Patients With Brain Metastases Revealed 10/21/2013 12:24:01 PM